Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size 2024-2028 

The vascular endothelial growth factor (vegf) inhibitors market size is forecast to increase by USD 11.67 billion at a CAGR of 8.09% between 2023 and 2028. The VEGF inhibitor market is experiencing significant growth due to the high target affinity and specificity of these inhibitors in treating various types of cancer, including breast, lung, bronchus, melanoma, and pancreatic cancer. A key trend in the market is the increasing popularity of combination therapies, which involve using multiple drugs in combination to enhance therapeutic efficacy. Additionally, there is a growing preference for gene therapy, which utilizes genes to treat or prevent diseases, in the development of new oncology candidates. One notable example is Molecular Partners' oncology candidate MP0250, which is a dual-targeting, bispecific T-cell engager designed to target both VEGF and PD-L1. This innovative approach has the potential to significantly improve cancer treatment outcomes. Overall, the VEGF inhibitor market is expected to continue its growth trajectory due to these market drivers and emerging trends.

 Request Free Sample

The VEGF inhibitor market represents a significant space in the biopharmaceutical industry, driven by the potential of these therapeutics in inhibiting angiogenesis, a critical process in cancer formation and various ophthalmic conditions. VEGF, a protein that plays a pivotal role in the development of new blood vessels, is a primary target for therapeutic intervention in various disease areas. In oncology, VEGF inhibitors have shown promise in treating various cancers, including ovarian, cervical, colon and rectum, prostate, breast, lung, and bronchus. These inhibitors work by blocking the action of VEGF, thereby inhibiting the formation of new blood vessels essential for tumor growth.

The pipeline for VEGF inhibitors is robust, with several promising candidates in various stages of development. Avastin, a well-known VEGF inhibitor, has been approved for the treatment of several types of cancer and macular edema, a common eye condition. In the field of eye care, VEGF inhibitors have gained significant attention due to their efficacy in treating conditions such as macular edema and retinal vein occlusion. These conditions are characterized by the development of new blood vessels in the eye, leading to vision loss. VEGF inhibitors, by blocking the action of VEGF, can help prevent the formation of these new blood vessels and improve vision.

The market for VEGF inhibitors is expected to face challenges due to the patent cliff for several key products. However, the development of biosimilar drugs offers opportunities for market growth. Biosimilar drugs are essentially generic versions of biologic drugs and offer significant cost savings to patients and healthcare providers. In conclusion, the VEGF inhibitor market presents significant opportunities for growth in the oncology and eye care sectors. The pipeline for new VEGF inhibitors is robust, and the potential applications in various disease areas are vast. The challenges posed by patent cliffs can be mitigated by the development of biosimilar drugs, offering cost-effective alternatives to patients and healthcare providers.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Application
  • Oncology
  • Ophthalmology
• Type
  • VEGF-A inhibitor
  • VEGF-B inhibitor
  • VEGF-C inhibitor
  • VEGF-D inhibitor
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
  • Asia
    • Japan
  • Rest of World (ROW)

By Application Insights

The oncology segment is estimated to witness significant growth during the forecast period.Vascular Endothelial Growth Factor (VEGF) inhibitors hold significant importance in the medical field, particularly in the oncology sector. In 2023, the oncology segment led the VEGF inhibitors market, accounting for the largest share, and this trend is projected to continue through 2028. The primary reason for this dominance is the approval of most VEGF inhibitors for oncology indications. The increasing incidence of various cancers worldwide, driven by gene mutations and lifestyle changes, fuels the growth of this segment. To address the vast unmet need, numerous companies are investing heavily in research and development of innovative therapeutics, including VEGF inhibitors. Osimertinib, a type of VEGF inhibitor, is a notable drug in this context.

However, like all medications, it comes with potential side effects. Some common side effects include hypertension, stroke, heart attack, and impaired wound healing. The Food and Drug Administration (FDA) has approved Osimertinib for the treatment of certain types of non-small cell lung cancer. Hepatocyte growth factor, another growth factor, plays a role in angiogenesis, the process of forming new blood vessels. VEGF inhibitors can interfere with this process, leading to the side effects mentioned above. In conclusion, the VEGF inhibitors market is driven by the growing demand for effective cancer treatments. The oncology segment, which includes drugs like Osimertinib, holds the largest market share due to the high prevalence of cancer and the approval of these drugs for oncology indications.

Despite their benefits, VEGF inhibitors come with potential side effects, such as hypertension, stroke, heart attack, and impaired wound healing. It is crucial for healthcare professionals to be aware of these risks and monitor patients closely during treatment.

Get a glance at the market share of various segments Request Free Sample

The Oncology segment accounted for USD 12518.90 million in 2018 and showed a gradual increase during the forecast period.

Regional Insights

North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions Request Free Sample

The VEGF inhibitor market in North America is experiencing significant growth due to the increasing number of approved treatments for conditions such as diabetic retinopathy and various ophthalmic disorders, including macular edema and retinal vein occlusion. According to the National Cancer Institute, approximately 28.5 million invasive cancer cases have been diagnosed in North America over the last two decades, with over one million new cases reported annually. Two of the most common cancer types in this region are NSCLC and RCC. The high prevalence of these cancers necessitates advanced and specialized treatment options, leading to a growing demand for VEGF inhibitors.

Brolucizumab, a new entrant in the market, is expected to bring competition and potentially lower costs with biosimilar drugs becoming increasingly available. The patent cliff for several leading VEGF inhibitors is also driving market growth as new treatments enter the market.

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Market Driver

High target affinity and specificity of VEGF inhibitors is the key driver of the market. In the realm of advanced or metastatic carcinomas, such as melanoma and NSCLC, as well as ophthalmic conditions like AMD and RVO, there remains a significant need for effective treatments with minimal side effects. Current therapies, including those approved in oncology and ophthalmology, have limitations. For example, chemotherapy, a standard treatment for cancer, targets dividing cells, making it effective against cancer cells but also damaging healthy cells. This leads to adverse effects, which can impact patient compliance. Vascular Endothelial Growth Factor (VEGF) inhibitors represent a promising solution for addressing these unmet needs. These proteins play a crucial role in angiogenesis, the process of new blood vessel formation, which is essential for cancer growth and ophthalmic conditions.

VEGF inhibitors can inhibit this process, thereby halting the growth of new blood vessels and preventing the progression of these conditions. One notable VEGF inhibitor is Avastin, which has shown efficacy in various cancers, including ovarian and cervical cancer. Another example is Tecentriq, which, in combination with chemotherapy, has demonstrated improved outcomes for NSCLC patients. By targeting VEGF, these therapies offer the potential for improved treatment efficacy with reduced side effects compared to traditional chemotherapy. In conclusion, the pipeline analysis for VEGF inhibitors holds significant promise for addressing the unmet needs in the treatment of various indications, including oncology and ophthalmology.

These therapies, by targeting VEGF and inhibiting angiogenesis, offer the potential for improved treatment outcomes with fewer side effects compared to existing therapies.

Market Trends

Growing popularity of combination therapies is the upcoming trend in the market. The VEGF inhibitors market encompasses a significant number of drugs utilized in the treatment of cancer and eye disorders. Pharmaceutical research indicates that certain metastatic cancers may not respond to monotherapy drugs. In response, the combination of drugs with distinct mechanisms of action has emerged as an effective strategy. By employing this approach, drugs can act synergistically at the target site, reducing the likelihood of resistant cancer cells developing. This trend is evident in both oncology and ophthalmic applications. For instance, in oncology, the use of combination chemotherapies has gained traction due to their ability to optimize therapeutic efficacy while minimizing side effects.

Similarly, in ophthalmology, the combination of VEGF inhibitors with other therapeutic agents has shown promising results in the treatment of various eye disorders. Molecular Partners, an oncology candidate, is one of the companies actively involved in the development of combination therapies using VEGF inhibitors.

Market Challenge

Preference for gene therapy is a key challenge affecting the market growth. In the realm of healthcare, small molecule drugs and targeted therapeutics have emerged as primary treatment options for various ophthalmology and oncology conditions. Recent advancements in oncology and ophthalmology research have shed light on the role of gene mutations in the development of certain carcinomas and eye disorders. These mutations occur as a result of cellular damage over a person's lifetime, leading to uncontrolled cell division and the formation of tumors, such as in breast or colon cells. Gene therapy represents the latest innovation in the treatment landscape, particularly in oncology. This therapeutic approach involves introducing genetic material into cells to rectify abnormal gene or protein production.

For instance, Vascular Endothelial Growth Factor (VEGF) inhibitors, like Cometriq and Eylea, have been developed to target specific gene mutations and inhibit their effects. Pharmaceutical companies, such as AbbVie, Allergan Aesthetics, and those specializing in neuroscience, are actively investing in research and development of these innovative therapies. VEGF inhibitors play a crucial role in the treatment of various conditions, including leukemia and prostate cancer. By inhibiting the production and activity of VEGF, these therapies can slow down or even halt the growth of tumors, ultimately improving patient outcomes. The potential of gene therapy in oncology and ophthalmology is vast, and continued research and investment are essential to unlocking its full potential and bringing life-changing treatments to patients.

Exclusive Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

AbbVie Inc. - The company provides vascular endothelial growth factor (VEGF) inhibitors, including ABBV642, as a therapeutic solution. VEGF inhibitors are essential medications used to manage various diseases, such as age-related macular degeneration, diabetic retinopathy, and cancer. These inhibitors work by blocking the action of VEGF, a protein that promotes the growth of new blood vessels. By inhibiting VEGF, these medications help prevent the progression of these conditions. The use of VEGF inhibitors has gained significant attention in the healthcare industry due to their potential benefits in improving patient outcomes. Keywords: VEGF inhibitors, ABBV642, therapeutic solution, vascular endothelial growth factor, age-related macular degeneration, diabetic retinopathy, cancer, protein, progression, patient outcomes.

The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca Plc
• Bausch Health Companies Inc.
• Bayer AG
• Bristol Myers Squibb Co.
• Clovis Oncology Inc.
• Eisai Co. Ltd.
• Eli Lilly and Co.
• Exelixis Inc.
• F. Hoffmann La Roche Ltd.
• LG Chem Ltd.
• Merck and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• Viatris Inc.
• Xbrane Biopharma AB

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

Vascular endothelial growth factor (VEGF) inhibitors are a class of proteins that play a crucial role in inhibiting the formation of new blood vessels during angiogenesis, a process involved in cancer formation and various ophthalmic conditions. These inhibitors have been extensively researched for their potential in treating various types of cancer, including ovarian, cervical, leukemia, prostate, breast, lung, bronchus, melanoma, and pancreatic cancer. Major pharmaceutical firms, such as AbbVie, Allergan Aesthetics, and Roche, have several VEGF inhibitors in their pipelines. Notable market rivals include Avastin, Tecentriq, Cometriq, Eylea, and several oncology candidates like MP0250 and Osimertinib. VEGF inhibitors have shown significant promise in cancer treatment by inhibiting tumor growth and metastasis.

However, they come with side effects such as hypertension, stroke, heart attack, impaired wound healing, and bleeding, among others. The FDA has approved several VEGF inhibitors for various indications, including Avastin for colorectal cancer and macular edema, Eylea for macular edema and retinal vein occlusion, and Cometriq for renal cell carcinoma. The production capacities of VEGF inhibitors are expanding, with biopharma firms investing in research activities to develop new molecular partners and expand their product outlook. However, the market faces challenges such as patent cliffs and the emergence of biosimilar drugs, which may impact the market growth. The future scope of VEGF inhibitors is vast, with potential applications in various ophthalmic conditions, including diabetic retinopathy, and other indications in hematologic oncology and neuroscience. Difficult challenges and threats, such as the emergence of biosimilar drugs and the need for continuous innovation, will require firms to stay agile and invest in research and development to maintain their market position.

Request Free Sample

What are the Key Data Covered in this Market Research and Growth Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market  and its contribution of the market in focus to the parent market
• Accurate predictions about upcoming market growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch